RESEARCH

Crosstalk of BMP-4 and RA signaling pathways on *Pomc* gene regulation in corticotrophs

Leandro Nieto^{1,*}, Mariana Fuertes^{1,*}, Josefina Rosmino^{1,2}, Sergio Senin¹ and Eduardo Arzt^{1,3}¹Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) – CONICET – Partner Institute of the Max Planck Society, Buenos Aires, Argentina²División Endocrinología, Hospital General de Agudos ‘Carlos G. Durand’, Buenos Aires, Argentina³Departamento de Fisiología y Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, ArgentinaCorrespondence should be addressed to E Arzt: earzt@ibioba-mpsp-conicet.gov.ar

*(L Nieto and M Fuertes contributed equally to this work)

Abstract

Retinoic acid (RA), an active metabolite of Vitamin A, and bone morphogenetic protein 4 (BMP-4) pathways control the transcription of pro-opiomelanocortin (*Pomc*), the precursor of ACTH. We describe a novel mechanism by which RA and BMP-4 act together in the context of pituitary corticotroph tumoral cells to regulate *Pomc* transcription. BMP-4 and RA exert a potentiated inhibition on *Pomc* gene expression. This potentiation of the inhibitory action on *Pomc* transcription was blocked by the inhibitory SMADs of the BMP-4 pathway (SMAD6 and SMAD7), a negative regulator of BMP-4 signaling (TOB1) and a blocker of RA pathway (COUP-TFI). AtT-20 corticotrophinoma cells express RA receptors (RAR β , RXRA and RXRG) which associate with factors of BMP-4 (SMAD4 and SMAD1) signaling cascade in transcriptional complexes that block *Pomc* transcription. COUP-TFI and TOB1 disrupt these complexes. Deletions and mutations of the *Pomc* promoter and a specific DNA-binding assay show that the complexes bind to the RARE site in the *Pomc* promoter. The enhanced inhibitory interaction between RA and BMP-4 pathways occurs also in another relevant corticotroph gene promoter, the corticotropin-releasing hormone receptor 1 (*Crh-r1*). The understanding of the molecules that participate in the control of corticotroph gene expression contribute to define more precise targets for the treatment of corticotrophinomas.

Key Words

- ▶ BMP-4
- ▶ retinoic acid
- ▶ POMC
- ▶ corticotroph
- ▶ Smad

Journal of Molecular
Endocrinology
(2019) **63**, 161–174

Introduction

Retinoic acid (RA), the active acid metabolite of Vitamin A, is a regulator of metabolic and cellular functions like cell differentiation, proliferation and apoptosis. RA acts mainly through a canonical pathway of gene expression regulation that involves the binding to nuclear RA receptors, which interact with specific regions in the DNA (Das *et al.* 2014) and are divided in two classes: RA receptors (RAR) and retinoid X receptors (RXRs). Three isoforms were described for RAR receptors, RARA,

RARB and RARG, while RXRA, RXRB and RXRG were described for RXR receptors (Maden 2007). Due to the ample variety of systemic processes in which RA participates, RA-modulating drugs have been used in certain clinical settings showing beneficial biological effects (Burnett *et al.* 2015, Abaza *et al.* 2017).

Cushing's disease originates in the excessive production of adrenocorticotrophic hormone (ACTH) by a secreting pituitary corticotrophinoma and as a result

of this over-production, the systemic level of circulating cortisol produced by the adrenal glands is dramatically increased (Dahia & Grossman 1999, Melmed 2015, Albani *et al.* 2018). Corticotroph adenomas derive from normal pituitary corticotroph cells and represent about 4–8% of the hormone-active tumors in the anterior pituitary (Dahia & Grossman 1999). Cushing's disease is a very low-incidence disorder with the prevalence of active corticotroph tumors being about 40 cases per million, with higher prevalence in women (Pivonello *et al.* 2015). Transsphenoidal surgery is, in principle, the first approach for a treatment. This surgery procedure is not always successful, especially when the tumor is not completely resected, in which case, over time might expand, generating the necessity of other therapeutical options like chemotherapy, radiotherapy, repeated surgery or pharmacological treatment. In some cases, adrenalectomy is the decision of choice (Pivonello *et al.* 2015). Therapies aiming to reduce the circulating cortisol mainly act directly on the adrenal cortex by either blocking the synthesis of, or antagonizing peripheral glucocorticoid receptors, thus inhibiting glucocorticoid action or modulating ACTH pituitary hormone secretion (Pedroncelli 2010, Fleseriu & Castinetti 2016, Fuertes *et al.* 2018, Grossman 2018, Langlois *et al.* 2018). Despite the ample variety of current available therapies (Fuertes *et al.* 2018), none has proven to be effective and to reliably provide a good, recurrence-free quality of life to the patient (Mooney *et al.* 2016, Bertagna 2018). The genetic and cellular mechanisms that underlie corticotrophinomas are poorly understood (Newell-Price *et al.* 2006), partially explaining the lack of effective treatments (Pivonello *et al.* 2015).

ACTH is derived from a 266 amino acid precursor polypeptide, pro-opiomelanocortin (*Pomc*) (Drouin 2016). The *Pomc* gene plays a central role among the hypothalamic–pituitary–adrenal axis regulatory mechanisms (Gagner & Drouin 1985, Ray *et al.* 1995). The transcription activity of this gene is highly upregulated in ACTH-secreting pituitary adenomas (Arzt *et al.* 1992, Dahia & Grossman 1999), thus suggesting *Pomc* transcriptional regulatory mechanisms as potential pharmacological targets. Recently, it was shown that proton-induced corticotropin-releasing hormone receptor 1 (*Crh-r1*) signaling regulates *Pomc* expression and ACTH production (Kameda *et al.* 2019).

Given its known role of inhibiting *Pomc* transcription, RA signaling is attractive as a target for long-term treatments. In this regard, RA treatment reduced ACTH secretion in the murine AtT-20 corticotrophinoma-like cell line and the proliferation rate of these cells

(Paez-Pereda *et al.* 2001). *In vivo* tumorigenesis studies using nude mice showed that RA treatment blocked the growth of corticotroph tumors compared to vehicle-treated ones, reverting the characteristic signs of high corticosterone levels (Paez-Pereda *et al.* 2001). A 6-to-12-month treatment scheme with RA in dogs with Cushing's disease not only normalized cortisol levels but prevented pituitary adenomas from recurring as well (Castillo *et al.* 2006). Two prospective clinical trials in human patients reported beneficial results in normalizing ACTH and cortisol levels after treatment with RA, for a period of 6–12 months (Pecori Giraldo *et al.* 2012, Vilar *et al.* 2016). The orphan nuclear receptor COUP-TFI negatively regulates retinoid action on target genes (Schuh & Kimelman 1995, Bertacchi *et al.* 2019). Consistent with the presence of COUP-TFI in normal pituitary cells and not in tumoral ones, ACTH levels were unaltered after RA treatment in non-tumoral corticotrophs (Paez-Pereda *et al.* 2001).

Interestingly, RA treatment induces the expression of bone morphogenetic protein-4 (BMP-4), a cytokine of the TGF β superfamily involved in multiple tissue and organ maturation and differentiation processes, particularly during pituitary development (Sheng *et al.* 1997, Cushman & Camper 2001, Davis *et al.* 2011). The mechanism mediating these actions involves the activation of specific signal transducers, the Smad proteins, which migrate to the nucleus to act as transcription factors (Shi & Massague 2003). Drugs acting at the epigenetic level have a permissive action for RA-induced expression of the *BMP* gene in pituitary tumor cells (Yacqub-Usman *et al.* 2013). The expression of BMP-4 is reduced in Cushing's corticotrophinoma cells compared to corticotrophs from normal pituitary glands (Giacomini *et al.* 2006). Reduced expression of BMP-4 in corticotrophinomas is associated with epigenomic silencing, and the coincubation with the demethylating agent zebularine or the histone deacetylase inhibitor, trichostatin A, reversed the epigenetic changes and restored the expression of BMP-4 (Yacqub-Usman *et al.* 2012). BMP-4 treatment reduced ACTH secretion and proliferation of AtT-20 mouse corticotrophs, effects which were blocked in stably expressing SMAD4-DN or noggin AtT-20 clones (Giacomini *et al.* 2006). BMP-4 represses *Pomc* promoter activity involving SMAD1/4 and the interference with Pitx/Tpit activity (Nudi *et al.* 2005). Tob1, a transcription factor participating in bone formation processes by blocking BMP-4/SMAD1/7 signaling in osteoblasts (Yoshida *et al.* 2000), takes part in the molecular events that control the actions of BMP-4.

To understand the regulatory mechanisms of *Pomc* expression by RA we analyzed in depth the signaling

receptors involved in the interaction with BMP-4 signaling pathways and their joint action on the inhibition of *Pomc* transcription. The observed interaction of both pathways, at transcriptional level, resulted in a marked inhibition of the mechanism leading to production of ACTH, evidencing an interconnected regulatory network. Complexes between the RA receptors and SMAD signaling molecules that are negatively regulated by COUP-TFI and Tob1 contribute to the transcriptional control of *Pomc* and provide the molecular basis to understand the action of both BMP-4 and RA on the *Pomc*–ACTH expression in corticotrophs.

Materials and methods

Unless otherwise stated, reagents were obtained from Life Technologies/Thermo Fisher Scientific or Sigma-Aldrich/Merck.

Cell culture

AtT-20 pituitary corticotroph tumor cells were obtained from the American Type Culture Collection. AtT-20 cells were cultured in low-glucose DMEM (pH 7.3) supplemented with 10% fetal calf serum (FCS), 2.2 g/L NaHCO₃, 10 mM HEPES, and 2 mM glutamine until they were confluent under 5% CO₂ atmosphere at 37°C. Cells were treated with 100 ng/mL BMP-4 (R&D Systems) or 100 nM all-*trans* RA that was dissolved in ethanol-DMSO as a 10 mM stock solution and handled in the dark. The diluting mixture was used in all the *in vitro* experiments as control.

Plasmids

The luciferase gene under the control of 770 bp of the rat *Pomc* promoter includes all the necessary sequences for the expression and regulation of *Pomc* in pituitary cells *in vivo* (Liu *et al.* 1992). The following *Pomc* promoter reporter constructs that present deletions or mutations in the *Pomc* promoter useful for our studies (Fig. 3A) were kindly given by Jacques Drouin (Therrien & Drouin 1991): JA289 (which contains a BMPRE deletion), JA361 (which contains a RARE deletion), JA316 (which contains a BMPRE point mutation) and JA327 (which contains a RARE point mutation). RARE-LUC reporter was kindly provided by Ethan Dmitrovsky (Petty *et al.* 2005). BMPRE-LUC and mouse TOB1 expression vector were generously given by Yutaka Yoshida (Yoshida *et al.* 2000). SMAD6 and SMAD7 expression vectors were

kindly given by Takeshi Imamura and Peter ten Dijke, respectively (Imamura *et al.* 1997, Nakao *et al.* 1997). COUP-TFI expression vector was kindly given by Ming-Jer Tsai (Pipaon *et al.* 1999). *Crh-r1*–LUC reporter vector is described elsewhere and was kindly given by Alon Chen (Kuperman *et al.* 2011).

Transfection and reporter assays

Cell transfection was performed with Lipofectamine and Plus Reagent according to manufacturer instructions and using standard procedures, as previously described (Paez-Pereda *et al.* 2001, Giacomini *et al.* 2006). After plating in 12-well plates, cells were transfected for 6 h in OPTIMEM using 2 µL of Lipofectamine, 1 µL of Plus Reagent and 1 µg total plasmid DNA per well. Cells were then washed and left to recover in DMEM overnight. The following day, cells were washed, left in serum-free DMEM for 6 h and treated for 24 h in serum-free DMEM with the indicated compounds. An additional 200 ng of the RSV-β-gal construct was co-transfected in all the experiments to correct for variations in transfection efficiency as previously described (Paez-Pereda *et al.* 2003). Luciferase activity was measured with a Junior luminometer (Berthold, Bad Wildbad, Germany). Results are shown as ratios of luciferase and β-galactosidase activity.

For transfections with SMAD6 and 7 expression vectors a dose–response curve was assayed from 0 to 500 ng of each plasmid and a dose of 100 ng was chosen for subsequent studies as this dose showed no alteration in basal activation levels.

A dose–response curve of TOB1 on *Pomc* transcription showed that from 100 to 300 ng, it stimulates the basal condition and most effectively blocks BMP-4 at 300 ng.

Western blot analysis

Western blot (WB) was performed as previously described (Paez-Pereda *et al.* 2003). Briefly AtT-20 cells were washed once with PBS (pH 7.0), and then cell lysates were prepared in standard cracking buffer and boiled for 5 min. Equal levels of protein (30 µg) were electrophoresed by SDS-PAGE. Proteins were blotted onto nitrocellulose Western blotting membranes (Amersham) using standard procedures and anti-RXRA (sc-553, 1:1,000), anti-RXRB (sc-56869, 1:1,000), anti-RXRG (sc-555, 1:1,000), anti-RARA (sc-551, 1:1,000), anti-RARB (sc-552, 1:1,000), anti-RARG (sc-7387, 1:1,000), anti-SMAD4 (sc-7966, 1:1,000), anti-SMAD1 (sc-7965, 1:1000) or anti-Actin (sc-47778, 1:5,000) (Santa Cruz Biotechnology Inc.) or

anti-pSMAD1/5 (Ser463/465, 41D10) (Cell Signaling) were added. The primary antibodies were detected with HRP-conjugated anti-rabbit IgG secondary antibodies (Bio-Rad). Blots were imaged using the G:Box Chemi XT4 (Synoptics Ltd., Cambridge, United Kingdom) with SuperSignal West Dura kit according to manufacturer's instruction (Pierce Biotechnology).

Immunoprecipitation (IP)

Cells were seeded in P100 plates to full confluence in DMEM. Before performing the treatment, DMEM was changed to serum-free DMEM for 6 h. Cells were treated in serum-free DMEM for 24 h with the indicated compound, washed with PBS, lysed on ice with modified RIPA buffer and immunoprecipitated with anti-SMAD4 or anti-SMAD1 using Protein G Agarose as described (Paez-Pereda *et al.* 2003). WB analyses were performed with the indicated antibodies. Mock control corresponds to the condition with all treatments present and immunoprecipitated with unspecific IgG of the same isotype of the antibody used to precipitate.

Hormone measurements

ACTH was determined by radioimmunoassay as previously described (Arzt *et al.* 1992).

Preparation of nuclear extracts

AtT-20 cells (9×10^6) were treated with RA, BMP-4 or vehicle for 24 h, and then harvested in 1 mL cold PBS containing 0.6 mM EDTA and pelleted at 5000g for 30 s. Nuclear extracts were prepared as previously described (Giacomini *et al.* 2009). Cell pellets were gently resuspended in 350 μ L cold buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride, 1 μ g/mL aprotinin and 1 μ g/mL pepstatin) and allowed to swell on ice for 10 min; then 5 mL of a 10% Igepal CA-630 solution was added to the cell suspensions, and cells were lysed on ice for 10 min and vortexed for 5 s every 2 min. After centrifugation at 12,000g for 20 min, the nuclear pellets were resuspended in 100 μ L cold buffer B (20 mM HEPES (pH 7.9), 600 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride and 25% glycerol), incubated for 40 min on ice and vortexed every 10 min. After removal of nuclear debris by centrifugation at 16,000g for 10 min at 4°C, the microextracts were stored at -80°C.

EMSA

EMSA was performed as previously described (Giacomini *et al.* 2009). Oligonucleotides were synthesized as single strand and the annealing of the complementary strands was allowed. Briefly, each oligonucleotide was dissolved to a final concentration of 1 mg/mL before use, the annealing reaction was performed in oligo annealing buffer (100 mM Tris-HCl (pH 7.5), 1 M NaCl and 10 mM EDTA) and equal volumes of both oligonucleotides were mixed and heated in a standard heat block at 95°C. The following oligonucleotides were annealed: 5'-AGCGCTGCCAGGAAGGTCACGTCCAAGGCT-1' and 5'-AGCCTTGGACGTGACCTTCC TGGCAGCG-1'. Oligonucleotides (1 μ g) were labeled using [α -32P]-dCTP and large-fragment DNA polymerase I (Klenow fragment). For binding reactions, nuclear extracts were incubated for 30 min at room temperature in a total volume of 30 μ L containing 25 mM HEPES (pH 7.2), 150 mM KCl, 10 mM DTT, 10% glycerol, 40 mM Spermidine and 500 μ g/mL poly(deoxyinosinic-deoxycytidylic) used as nonspecific competitor DNA, with 50000 cpm labeled probe. The samples were resolved on 6% polyacrylamide gels (acrylamide/bisacrylamide ratio of 29:1), buffered and ran for about 1.5 h in 0.5% TBE at room temperature (1 $\times$ TBE is 45 mM Tris/borate/1 mM EDTA). Anti-Smad4 antibody, anti-RAR β antibody, anti-RXR α antibody or anti-actin antibody (Santa Cruz Biotechnology Inc.) as control, were added to the nuclear extracts and incubated for 30 min at room temperature after addition of the probe. After incubation, the binding reaction mixture was applied to the gel as described above.

Statistical analysis

Statistical analyses were performed by ANOVA in combination with the Bonferroni *post hoc* test. Data are shown as mean $\pm$ S.E.M.

Results

BMP-4 potentiates RA inhibitory effect on *Pomc* transcription

We first evaluated the interaction of RA and BMP-4 on ACTH secretion in AtT-20 cells and observed a potentiated inhibitory effect of RA in co-treatment with BMP-4 (Fig. 1A). We evaluated if this interaction occurs on the *Pomc* promoter and observed that single RA or BMP-4 treatments reduced luciferase expression in the *Pomc* reporter assay by approximately 50%, with co-treatment

leading to a slight but significant further reduction (Fig. 1B). The extend of potentiation of the inhibition when BMP-4 was combined with RA was 16–37% with respect to RA alone. The inhibitory effect of RA or BMP-4 and also the potentiation of this inhibition by the co-treatment was abolished in the presence of 100ng of the inhibitors of BMP-4 signaling, SMAD 6 or SMAD 7 (Fig. 1B). BMP-4 (3.9-folds) or RA (1.9-folds) treatment increased the phosphorylation of SMAD1/5 (which nicely mirrors its action show in Fig. 1B) which was not further altered by the co-treatment (four-folds) (Fig. 1C). Based on this, it looks possible that additional phosphorylation occurs with co-treatment.

To further study the crosstalk of BMP-4 and RA signaling pathways, we evaluated the effect of the co-treatment with specific reporters for both cascades. We observed an increase in transcriptional activation of RARE reporter after RA treatment, thus highlighting the importance of the DNA context of the RARE site (Buchler *et al.* 2003, Segal & Widom 2009), which was potentiated by the co-treatment with BMP-4 (Fig. 1D). BMP-4 alone did not activate RARE transcription (Fig. 1D). In presence of SMAD 6 or SMAD 7, RA activated RARE transcription, but no activation enhancement was observed by the co-treatment with BMP-4 (Fig. 1D). BMP-4-specific SMAD-binding element reporter (BMPRE) showed activation by BMP-4, but no potentiated activation effect by the co-treatment with RA. RA alone did not activate BMPRE transcription (Fig. 1E). Consistent with cooperation between BMP and RA signaling in *Pomc* transcriptional inhibition, RA treatment failed to repress the *Pomc* reporter in AtT-20 cell clones that stably expressed a dominant negative SMAD4 protein (AtT-20 SMAD4-DN) (Fig. 1F).

RA and BMP-4 signaling factors associate to form transcriptional complexes

AtT-20 cells express the isoforms β and γ of the RA receptors (RAR) family, and the isoforms α , β and γ of the RXR family (Fig. 2A). We studied by IP assays in cells treated with RA or BMP-4, whether any of these receptors associate with factors of the BMP-4 signaling pathway. Smad4, the common TGF β /BMP-SMAD signaling mediator, forms complexes with RARB, RXRA and RXRG (Fig. 2B). We studied the formation of complexes of RA receptors with SMAD1, a specific BMP-4 pathway signaling molecule, and observed interaction with RARB, RXRA and RXRG (Fig. 2C), the same isoforms as for SMAD4.

Pomc promoter contains putative response elements for RA and BMP

We analyzed the sequence of the promoter region of rat *Pomc* (–483 to +63 bp) with BLAST tool and INSECT 2.0 software (Rohr *et al.* 2013, Parra *et al.* 2016) and found two putative response elements, one for RA (RARE site), located between the –68 and –63 bp in the proximal segment of the *Pomc* promoter, and a BMP response element (BMPRE), located between –423 and –419 bp in the distal segment of the promoter (Fig. 3A). The relevance of those sites was validated functionally by the loss of response to RA and BMP respectively (Fig. 3B and C). With different reporter constructs containing deletions (Fig. 3B) or mutations (Fig. 3C) of the *Pomc* promoter, we observed that in the reporter containing only the RARE site (Fig. 3B, *Pomc* promoter with RARE site – BMPRE deletion) both the inhibition by RA and the potentiation of the co-treatment with BMP-4 are preserved. Similar results were obtained in the point mutation construct for BMPRE (Fig. 3C, Mutated BMPRE site). In the *Pomc* construct containing only the BMPRE site (Fig. 3B, *Pomc* promoter with BMPRE site – RARE deletion), we observed no inhibitory effect by RA treatment and no potentiation in co-treatment with BMP-4. This observation was corroborated in the point mutation construct for RARE (Fig. 3C, mutated RARE site).

In an EMSA assay using the RARE sequence as radiolabeled probe to assess the formation of protein complexes with this sequence, we observed the formation of complexes for AtT-20 cell nuclear extracts after BMP-4 or RA treatment or co-treatment. In the absence of RA, a binding is observed, which is in agreement with the constitutive complex observed with similar conditions in Fig. 2. The complex formed in the co-treatment condition was disrupted in the presence of anti-SMAD4 but not anti-Actin, showing that SMAD4 is part of the complex that binds to the RARE site. Moreover, when we evaluated RA treatment and RA/BMP-4 co-treated condition with anti-RARB and anti-RXRA, the complexes formed were also displaced by the antibodies, revealing the presence of these RA receptors (Fig. 3D).

COUP-TFI blocks RA-mediated transcriptional repression of *Pomc*

COUP-TFI, a known negative regulator of RA signaling, disrupted the formation of the transcriptional complexes between RXRA, RXRG or RARB with SMAD4 in all the treatment conditions assayed (Fig. 4A). The interaction of RXRA or RARB with SMAD1 (Fig. 4B) was also disrupted,

Figure 1

RA inhibitory action on ACTH secretion and *Pomc* transcription is increased by the BMP-4 signaling pathway. (A) AtT-20 cells were treated for 24 h with BMP-4, RA, or their combinations as indicated, under CRH (100 nM) treatment. ACTH was measured in the supernatants by radioimmunoassay, and the average of three wells per treatment and s.e.m. from one representative experiment of three with similar results are shown. *** $P < 0.001$; ANOVA with Bonferroni contrast. (B) AtT-20 cells were co-transfected with *Pomc*-LUC reporter vector (500 ng), RSV- β -gal construct (200 ng) and SMAD6 or SMAD7 expression vector (100 ng) or empty vector and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean $\pm$ s.e.m. of luciferase to β -galactosidase ratio of one representative experiment of four with similar results are shown. * $P < 0.05$; *** $P < 0.001$; ANOVA with Bonferroni contrast. (C) pSMAD1/5 expression was studied by WB in AtT-20 cells treated with BMP-4, RA or their combination as indicated. (D) AtT-20 cells were co-transfected with RARE-LUC reporter vector (500 ng), RSV- β -gal construct (200 ng) and SMAD6 or SMAD7 expression vector (100 ng) or empty vector and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean $\pm$ s.e.m. of luciferase to β -galactosidase ratio of one representative experiment of four with similar results are shown. *** $P < 0.001$; n.s., not significant; ANOVA with Bonferroni contrast. (E) AtT-20 cells were co-transfected with BMPRE-LUC reporter vector (500 ng) and RSV- β -gal construct (200 ng), and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean $\pm$ s.e.m. of luciferase to β -galactosidase ratio of one representative experiment of three with similar results are shown. ** $P < 0.01$; n.s., not significant; ANOVA with Bonferroni contrast. (F) AtT-20 cells or AtT-20 SMAD4-DN stable clones were co-transfected with *Pomc*-LUC reporter vector (500 ng) and RSV- β -gal construct (200 ng) and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean $\pm$ s.e.m. of luciferase to β -galactosidase ratio of one representative experiment of three with similar results are shown. ** $P < 0.01$; *** $P < 0.001$; ANOVA with Bonferroni contrast.

while that for RXRG and SMAD1 was diminished only in the presence of BMP-4 and RA. The expression of COUP-TFI blocked the effect of RA treatment in both the *Pomc* and RARE reporters, as well as the potentiation exerted by the co-treatment with BMP-4 and RA (Fig. 4C and D). As a control, we further analyzed the effect of COUP-TFI in the *Pomc* promoter constructs with deletion (Fig. 4E) or mutation (Fig. 4F) of the BMPRE site. Consistent with the previous results, as expected, the presence of COUP-TFI blocked the inhibition exerted by the treatment with RA and the potentiation with BMP-4 in both *Pomc* constructs.

TOB1 specifically blocks BMP-4 inhibition on POMC transcription

We next examined whether TOB1, a negative regulator of the BMP-4 pathway (Yoshida *et al.* 2000, Cao & Chen 2005) affected the formation of the transcriptional complexes in AtT-20 cells. The expression of TOB1 hampered the formation of the complexes between RXRA, RXRG or RARB with SMAD4 (Fig. 5A). The same IP profile was obtained for the interaction between RXRA, RXRG or RARB with SMAD1 (Fig. 5B). TOB1 blocked the formation of these complexes though its effect was slightly less potent in comparison with SMAD4. The expression of TOB1 (300 ng) nullified the inhibitory action of BMP-4 treatment on *Pomc* and stimulated the basal condition, probably because it abolishes the action of the endogenous proteins (Fig. 5C).

The potentiated activation in transcription exerted by RA and BMP-4 co-treatment on RARE reporter was blocked by the presence of TOB1, which did not block the activation produced by RA treatment (Fig. 5D).

RA and BMP-4 signaling interaction is also exhibited for *Crh-r1* promoter

We next analyzed the *Crh-r1* promoter in order to examine if the mechanism of transcriptional regulation shown on the *Pomc* promoter by the crosstalk of RA and BMP-4 signaling pathways, takes place also in another corticotroph physiologically related regulation system. In accordance with the analysis of the *Pomc* promoter, in the sequence of the promoter region of mouse *Crh-r1* (−2685 to +217bp), we found with the INSECT 2.0 software (Rohr *et al.* 2013, Parra *et al.* 2016) one putative response element for RA (RARE site), in addition to four putative response elements for BMP (BMPRE site) (Fig. 6A). For this reporter, the transcriptional activation was also inhibited by the treatment of RA or BMP-4 (Fig. 6B). RA and BMP-4 co-treatment showed a potentiated inhibitory response. To assess the hypothesis of BMP-4 signaling pathway participation, the same functional experiment was performed in AtT-20 SMAD4-DN cells. In these cells, the effect of the treatment with RA or BMP-4 on *Crh-r1* promoter was completely nullified (Fig. 6B).

Figure 2

AtT-20 corticotroph cells express RA receptors, which interact with elements of the BMP-4 signaling pathway. (A) Retinoid and Rexinoid receptors (RAR and RXR) expression was studied by WB in AtT-20 cells and the specific band is indicated by an arrow. Cell extracts from HeLa (for RARA, RARG and RXRs) or HEK293T (for RARB) were used as positive controls. (B and C) AtT-20 cells were treated for 24 h with BMP-4, RA or their combination as indicated. Cell lysates were IP with anti-SMAD4 (1 µg) (B) or anti-SMAD1 (1 µg) (C) and analyzed by WB. M, mock. One representative of three independent experiments with similar results is shown.

Figure 3

RARE and BMPRE sites at the *Pomc* promoter. (A) Schematic representation of rat *Pomc* promoter (GenBank: X03171.1) in which we found by *in silico* analysis two consensus sequence, one for RA (RARE site, -63 to -68) and one for BMP (BMPRE site, -419 to -423). The scheme shows the distal (dotted), central (gray), proximal (lined) and minimal (white) promoter regions, and the different *Pomc* constructs used (complete promoter, with RARE site or with BMPRE site only, and mutated BMPRE site or RARE site). (B and C) At-20 cells were co-transfected with *Pomc*-LUC constructs (500 ng) and RSV-β-gal vector (200 ng), and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean $\pm$ S.E.M. of luciferase-to-β-galactosidase ratio of one representative experiment of three with similar results are shown. n.s., not significant; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; ANOVA with Bonferroni contrast. (D) EMSA of binding reactions using RARE sequence of the *Pomc* promoter as probe and At-20 cell nuclear extracts (NE) treated with BMP-4, RA or their combination as indicated. Binding complex is indicated by an arrow. Anti-SMAD4, anti-RARβ and anti-RXRα antibodies (2 μg) were used to disrupt the binding complex; anti-actin antibody was used as control. Unlabeled probe was used as competitor to displace the formed complex. The experiment shown is representative for two independent experiments with similar results.

Discussion

RA and BMP-4 have shown to be involved in the regulation of corticotrophinoma growth and hormone

production, but their interrelation on *Pomc* transcription had not been analyzed until now. Our work describes a novel mechanism by which RA receptors of both the RAR and RXR families interact with SMADs, the signal

Figure 4

COUP-TFI hampers the formation of transcriptional complexes between elements of the BMP-4 signaling pathway and RA receptors. (A and B) AtT-20 cells were transfected with COUP-TFI expression vector or empty vector and treated for 24 h with BMP-4, RA or their combination as indicated. Cell lysates were IP with anti-SMAD4 (1 µg) (A) or anti-SMAD1 (1 µg) (B) and analyzed by WB. One representative of three independent experiments with similar results is shown. V, vehicle; B, 100 ng/mL BMP-4; R, 100 nM RA; BR, 100 ng/mL BMP-4 + 100 nM RA; M, mock. (C, D, E and F) AtT-20 cells were co-transfected with POMC-LUC (C) or RARE-LUC (D) or *Pomc* promoter with BMPRE deletion (E) or *Pomc* promoter with BMPRE mutation (F) reporter vector (500 ng), RSV-β-gal construct (200 ng) and COUP-TFI expression vector (400 ng) or empty vector and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean $\pm$ s.e.m. of luciferase-to-β-galactosidase ratio of one representative experiment of three with similar results are shown. n.s., not significant; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; ANOVA with Bonferroni contrast.

transducers of the BMP-4 pathway. BMP-4 reduces the transcriptional activity of *Pomc*, enhancing the inhibitory effect of RA. RA receptors and SMAD proteins associate by forming transcriptional complexes that bind to the RARE consensus sequence in the *Pomc* promoter. Negative regulators of RA and BMP-4 pathways, COUP-TFI and

TOB1, disrupt the combined transcriptional complexes reversing the *Pomc* inhibition.

RA has an inhibitory effect on tumoral growth in AtT-20 pituitary corticotroph cells (Paez-Pereda *et al.* 2001). The blockade of BMP-4 pathway by hampering Smad4 diminishes the inhibitory effect of RA on tumoral cell

Figure 5

TOB1 disrupts the formation of transcriptional complexes between RA receptors and elements of the BMP-4 signaling. (A and B) AtT-20 cells were transfected with TOB1 expression vector or empty vector and treated for 24 h with BMP-4, RA or their combination as indicated. Cell lysates were IP with anti-SMAD4 (1 µg) (A) or anti-SMAD1 (1 µg) (B) and analyzed by WB. One representative of two independent experiments with similar results is shown. V, vehicle; B, 100 ng/mL BMP-4; R, 100 nM RA; BR, 100 ng/mL BMP-4 + 100 nM RA; M, mock. (C and D) AtT-20 cells were co-transfected with *Pomc*-LUC (C) or RARE-LUC (D) reporter vector (500 ng), RSV-β-gal construct (200 ng) and TOB1 expression vector (300 ng) or empty vector, and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase-to-β-galactosidase ratio of one representative experiment of three with similar results are shown. n.s., not significant; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; ANOVA with Bonferroni contrast.

proliferation and RA induces the expression of BMP-4 (Giacomini *et al.* 2006). It was also demonstrated that both RA and BMP-4 inhibit *Pomc* transcription and ACTH production (Paez-Pereda *et al.* 2001, Nudi *et al.* 2005). In this paper, we demonstrate for the first time the molecular mechanism involved in the interaction of both pathways in regulating *Pomc* expression in corticotrophs.

The involvement of retinoic mediators in the BMP signaling has been also observed in mechanisms such as chondrogenesis. RA produced the inhibition of the phosphorylation of SMAD2 and SMAD3 and increased expression of SMAD7, explaining the RA-induced hypochondrogenesis of embryonic mesenchymal cells *in vitro* and showing a role of RA signaling in the mechanism of regulation of TGFB3/SMAD pathway (Yu & Xing 2006). RARγ may function as coactivator of SMAD3 and SMAD4 for TGFB-transactivation pathways in a ligand-specific manner (Pendaries *et al.* 2003). RA is a known potent inhibitor of adipogenesis. The involvement of SMAD3 in

the RA inhibition of pre-adipocytes has been described (Marchildon *et al.* 2010).

The BMP-Smad pathway interaction with steroid receptors seems to be an important mechanism for its action. In lactotrophs, BMP-4 signaling exerts a stimulatory and pro-proliferative signal, in contrast to what is observed in corticotrophs (Giacomini *et al.* 2009). In these cells BMP-4 interacts with estrogens both for its proliferative action as well as for the regulation of the prolactin promoter (Paez-Pereda *et al.* 2003, Giacomini *et al.* 2009). BMP-4 also decreased follicle-stimulating hormone (FSH) release in the sheep pituitary and amplified the suppression of FSH release and *FSHB* mRNA levels induced by 17β-estradiol *in vitro* (Faure *et al.* 2005). The crosstalk between SMADs and estrogens in cell proliferation in other systems has also been described (Matsuda *et al.* 2001, Kang *et al.* 2002). In corticotrophs the interaction seems to show no ligand dependency in so far as the complexes are formed in both cellular and

constitution of a functional pituitary gland. BMP-2 and BMP-4 have been shown to participate in the initial steps of the development of the anterior pituitary (Scully & Rosenfeld 2002). BMP-4 is particularly critical during the developmental patterning of the pituitary, from the induction of Rathke's pouch to cell specificity commitment in anterior lobe. The regulation in the expression and range of action of the factors present in this network governing the process is complex and the proper balance in the activity of BMP signaling is crucial in pituitary organogenesis (Davis & Camper 2007). Both BMP-4 and RA participate in multiple steps during pituitary development, controlling the circuitry of several signals

aiming to enhance the differentiation and maturation processes, mediated by the induction of expression of several key transcription factors (Cushman & Camper 2001, Suh *et al.* 2002). RA controls BMP-2 and BMP-4 regulation in embryonal carcinoma cells (Glozak & Rogers 1996), and their combination favors smooth muscle cell differentiation by inducing apoptosis in neurons and glial cells (Glozak & Rogers 1998, 2001). Intriguingly, as we show in this work, these pathways interact in the adult cell, in particular in the undifferentiated tumoral cells.

In order to verify if the RA–BMP-4 signaling complex is specific for the *Pomc* gene or could be acting on other target genes in the corticotroph, we investigated the *Crh-r1* gene. This gene promoter also presents RARE and BMPRE motifs and when evaluated under RA or BMP-4 treatment showed similar inhibitory effects as well as a potentiated inhibition under the co-treatment. The sensitivities of these systems are presumably to be different as the *Crh-r1* gene promoter showed a significantly lower inhibitory threshold of concentrations for both compounds to achieve a blockade in the transcriptional activation, in comparison to those required for *Pomc* inhibition. Other genes, under the control of RA and BMP-4 might be under the regulation of similar RA receptors/SMAD crosstalk mechanisms.

It has been observed that COUP-TFI expression in the normal pituitary is the reason why RA does not act on these cells (Paez-Pereda *et al.* 2001). In contrast, it has been shown that most of the human corticotrophinoma samples (29 out of 34) have negative expression for COUP-TFI (Bush *et al.* 2010). Therefore the clinical relevance of COUP-TFI could be a point to consider during the evaluation of a therapeutical approach. TOB1, a factor involved in osteoblast proliferation and bone formation processes, is a known BMP pathway inhibitor (Yoshida *et al.* 2000), and might have a potential role in the pituitary serving as a molecular tool to regulate BMP-4 action in corticotrophs. BMP-4 not only participates in the RA but also in the somatostatin analogs signaling on corticotrophinomas (Tsukamoto *et al.* 2010). Given the blocking action of TOB1 in the RA/BMP-4 interaction on *Pomc* transcription, its expression in tumoral corticotrophs could eventually hamper the clinical outcome of RA or other therapeutical scheme, underlying the significance of a proper biochemical characterization of the corticotrophinoma cases to be treated.

In conclusion, our study reveals a molecular mechanism in which the presence of co-regulatory elements of RA and BMP-4 signaling pathways interact to regulate *Pomc* transcriptional activity (Fig. 6C).

The expression of the molecules involved in these regulatory mechanisms will impact on the outcome of the response and may be relevant in order to define therapeutic targets for the treatment of corticotrophinomas.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by grants from the Max Planck Society, Germany; the University of Buenos Aires (grant number 20020170100230BA); CONICET (grant number D449 (01-03-2016)); the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) (grant numbers PID-CLINICO-2014-0024 and PICT2016-1620), Argentina; and FOCEM-Mercosur (COF 03/11).

Author contribution statement

L N, M F, J R and S S performed the experiments. L N, M F and E A analyzed the data. E A designed research. L N, M F and E A wrote the manuscript. All authors approved the final manuscript.

References

- Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, *et al.* 2017 Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. *Blood* **129** 1275–1283. (<https://doi.org/10.1182/blood-2016-09-736686>)
- Albani A, Theodoropoulou M & Reincke M 2018 Genetics of Cushing's disease. *Clinical Endocrinology* **88** 3–12. (<https://doi.org/10.1111/cen.13457>)
- Arzt E, Stelzer G, Renner U, Lange M, Muller OA & Stalla GK 1992 Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. *Journal of Clinical Investigation* **90** 1944–1951. (<https://doi.org/10.1172/JCI116072>)
- Bertacchi M, Parisot J & Studer M 2019 The pleiotropic transcriptional regulator COUP-TFI plays multiple roles in neural development and disease. *Brain Research* **1705** 75–94. (<https://doi.org/10.1016/j.brainres.2018.04.024>)
- Bertagna X 2018 MANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing's disease? A personal view. *European Journal of Endocrinology* **178** R183–R200. (<https://doi.org/10.1530/EJE-18-0062>)
- Buchler NE, Gerland U & Hwa T 2003 On schemes of combinatorial transcription logic. *PNAS* **100** 5136–5141. (<https://doi.org/10.1073/pnas.0930314100>)
- Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, *et al.* 2015 Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. *Lancet: Oncology* **16** 1295–1305. ([https://doi.org/10.1016/S1470-2045\(15\)00193-X](https://doi.org/10.1016/S1470-2045(15)00193-X))
- Bush ZM, Lopes MB, Hussaini IM, Jane Jr JA, Laws Jr ER & Vance ML 2010 Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. *Pituitary* **13** 1–7. (<https://doi.org/10.1007/s11102-009-0189-8>)

- Cao X & Chen D 2005 The BMP signaling and in vivo bone formation. *Gene* **357** 1–8. (<https://doi.org/10.1016/j.gene.2005.06.017>)
- Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer E, Grossman AB, Stalla GK & Arzt E 2006 Retinoic acid as a novel medical therapy for Cushing's disease in dogs. *Endocrinology* **147** 4438–4444. (<https://doi.org/10.1210/en.2006-0414>)
- Cushman LJ & Camper SA 2001 Molecular basis of pituitary dysfunction in mouse and human. *Mammalian Genome* **12** 485–494. (<https://doi.org/10.1007/s003350040002>)
- Dahia JL & Grossman AB 1999 The molecular pathogenesis of corticotroph tumors. *Endocrine Reviews* **20** 136–155. (<https://doi.org/10.1210/edrv.20.2.0358>)
- Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, *et al.* 2014 Retinoic acid signaling pathways in development and diseases. *Bioorganic and Medicinal Chemistry* **22** 673–683. (<https://doi.org/10.1016/j.bmc.2013.11.025>)
- Davis SW & Camper SA 2007 Noggin regulates Bmp4 activity during pituitary induction. *Developmental Biology* **305** 145–160. (<https://doi.org/10.1016/j.ydbio.2007.02.001>)
- Davis SW, Mortensen AH & Camper SA 2011 Birthdating studies reshape models for pituitary gland cell specification. *Developmental Biology* **352** 215–227. (<https://doi.org/10.1016/j.ydbio.2011.01.010>)
- Drouin J 2016 60 YEARS OF POMC: Transcriptional and epigenetic regulation of POMC gene expression. *Journal of Molecular Endocrinology* **56** T99–T112. (<https://doi.org/10.1530/JME-15-0289>)
- Faure MO, Nicol L, Fabre S, Fontaine J, Mohoric N, Mcneilly A & Taragnat C 2005 BMP-4 inhibits follicle-stimulating hormone secretion in ewe pituitary. *Journal of Endocrinology* **186** 109–121. (<https://doi.org/10.1677/joe.1.05988>)
- Fleseriu M & Castinetti F 2016 Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. *Pituitary* **19** 643–653. (<https://doi.org/10.1007/s11102-016-0742-1>)
- Fuertes M, Tkach J, Rosmino J, Nieto L, Guitelman MA & Arzt E 2018 New insights in Cushing disease treatment With focus on a derivative of vitamin A. *Frontiers in Endocrinology* **9** 262. (<https://doi.org/10.3389/fendo.2018.00262>)
- Gagner JP & Drouin J 1985 Opposite regulation of pro-opiomelanocortin gene transcription by glucocorticoids and CRH. *Molecular and Cellular Endocrinology* **40** 25–32. ([https://doi.org/10.1016/0303-7207\(85\)90154-6](https://doi.org/10.1016/0303-7207(85)90154-6))
- Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M, *et al.* 2006 Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. *Endocrinology* **147** 247–256. (<https://doi.org/10.1210/en.2005-0958>)
- Giacomini D, Paez-Pereda M, Stalla J, Stalla GK & Arzt E 2009 Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: impact on the PRL promoter. *Molecular Endocrinology* **23** 1102–1114. (<https://doi.org/10.1210/me.2008-0425>)
- Glozak MA & Rogers MB 1996 Specific induction of apoptosis in P19 embryonal carcinoma cells by retinoic acid and BMP2 or BMP4. *Developmental Biology* **179** 458–470. (<https://doi.org/10.1006/dbio.1996.0275>)
- Glozak MA & Rogers MB 1998 BMP4- and RA-induced apoptosis is mediated through the activation of retinoic acid receptor alpha and gamma in P19 embryonal carcinoma cells. *Experimental Cell Research* **242** 165–173. (<https://doi.org/10.1006/excr.1998.4075>)
- Glozak MA & Rogers MB 2001 Retinoic acid- and bone morphogenetic protein 4-induced apoptosis in P19 embryonal carcinoma cells requires p27. *Experimental Cell Research* **268** 128–138. (<https://doi.org/10.1006/excr.2001.5281>)
- Grossman A 2018 Is the new treatment for Cushing's disease too sweet? *Lancet: Diabetes and Endocrinology* **6** 2–3. ([https://doi.org/10.1016/S2213-8587\(17\)30341-8](https://doi.org/10.1016/S2213-8587(17)30341-8))
- Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M & Miyazono K 1997 Smad6 inhibits signalling by the TGF-beta superfamily. *Nature* **389** 622–626. (<https://doi.org/10.1038/39355>)
- Kameda H, Yamamoto M, Tone Y, Tone M & Melmed S 2019 Proton sensitivity of corticotropin-releasing hormone receptor 1 signaling to proopiomelanocortin in male mice. *Endocrinology* **160** 276–291. (<https://doi.org/10.1210/en.2018-00920>)
- Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ & Chang C 2002 Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. *Journal of Biological Chemistry* **277** 43749–43756. (<https://doi.org/10.1074/jbc.M205603200>)
- Kuperman Y, Issler O, Vaughan J, Bilezikian J, Vale W & Chen A 2011 Expression and regulation of corticotropin-releasing factor receptor type 2beta in developing and mature mouse skeletal muscle. *Molecular Endocrinology* **25** 157–169. (<https://doi.org/10.1210/me.2010-0308>)
- Langlois F, Chu J & Fleseriu M 2018 Pituitary-directed therapies for Cushing's disease. *Frontiers in Endocrinology* **9** 164. (<https://doi.org/10.3389/fendo.2018.00164>)
- Liu B, Hammer GD, Rubinstein M, Mortrud M & Low MJ 1992 Identification of DNA elements cooperatively activating proopiomelanocortin gene expression in the pituitary glands of transgenic mice. *Molecular and Cellular Biology* **12** 3978–3990. (<https://doi.org/10.1128/mcb.12.9.3978>)
- Maden M 2007 Retinoic acid in the development, regeneration and maintenance of the nervous system. *Nature Reviews: Neuroscience* **8** 755–765. (<https://doi.org/10.1038/nrn2212>)
- Marchildon F, St-Louis C, Akter R, Roodman V & Wiper-Bergeron NL 2010 Transcription factor Smad3 is required for the inhibition of adipogenesis by retinoic acid. *Journal of Biological Chemistry* **285** 13274–13284. (<https://doi.org/10.1074/jbc.M109.054536>)
- Matsuda T, Yamamoto T, Muraguchi A & Saaticioglu F 2001 Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. *Journal of Biological Chemistry* **276** 42908–42914. (<https://doi.org/10.1074/jbc.M105316200>)
- Melmed S 2015 Pituitary tumors. *Endocrinology and Metabolism Clinics of North America* **44** 1–9. (<https://doi.org/10.1016/j.ecl.2014.11.004>)
- Mooney MA, Simon ED & Little AS 2016 Advancing treatment of pituitary adenomas through targeted molecular therapies: the Acromegaly and Cushing disease paradigms. *Frontiers in Surgery* **3** 45. (<https://doi.org/10.3389/fsurg.2016.00045>)
- Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, *et al.* 1997 Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. *Nature* **389** 631–635. (<https://doi.org/10.1038/39369>)
- Newell-Price J, Bertagna X, Grossman AB & Nieman LK 2006 Cushing's syndrome. *Lancet* **367** 1605–1617. ([https://doi.org/10.1016/S0140-6736\(06\)68699-6](https://doi.org/10.1016/S0140-6736(06)68699-6))
- Nudi M, Ouimette JF & Drouin J 2005 Bone morphogenetic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. *Molecular Endocrinology* **19** 1329–1342. (<https://doi.org/10.1210/me.2004-0425>)
- Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, *et al.* 2001 Retinoic acid prevents experimental Cushing syndrome. *Journal of Clinical Investigation* **108** 1123–1131. (<https://doi.org/10.1172/JCI11098>)
- Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST, *et al.* 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. *PNAS* **100** 1034–1039. (<https://doi.org/10.1073/pnas.0237312100>)
- Parra RG, Rohr CO, Koile D, Perez-Castro C & Yankilevich P 2016 INSECT 2.0: a web-server for genome-wide cis-regulatory modules

- prediction. *Bioinformatics* **32** 1229–1231. (<https://doi.org/10.1093/bioinformatics/btv726>)
- Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontecorvi A & Cavagnini F 2012 Potential role for retinoic acid in patients with Cushing's disease. *Journal of Clinical Endocrinology and Metabolism* **97** 3577–3583. (<https://doi.org/10.1210/jc.2012-2328>)
- Pedroncelli AM 2010 Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. *Neuroendocrinology* **92** 120–124. (<https://doi.org/10.1159/000314352>)
- Pendaries V, Verrecchia F, Michel S & Mauviel A 2003 Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner. *Oncogene* **22** 8212–8220. (<https://doi.org/10.1038/sj.onc.1206913>)
- Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ & Dmitrovsky E 2005 A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. *Journal of the National Cancer Institute* **97** 1645–1651. (<https://doi.org/10.1093/jnci/dji371>)
- Pipaon C, Tsai SY & Tsai MJ 1999 COUP-TF upregulates NGFI-A gene expression through an Sp1 binding site. *Molecular and Cellular Biology* **19** 2734–2745. (<https://doi.org/10.1128/mcb.19.4.2734>)
- Pivonello R, De Leo M, Cozzolino A & Colao A 2015 The treatment of Cushing's disease. *Endocrine Reviews* **36** 385–486. (<https://doi.org/10.1210/er.2013-1048>)
- Ray DW, Gibson S, Crosby SR, Davies D, Davis JR & White A 1995 Elevated levels of adrenocorticotropin (ACTH) precursors in post-adrenalectomy Cushing's disease and their regulation by glucocorticoids. *Journal of Clinical Endocrinology and Metabolism* **80** 2430–2436. (<https://doi.org/10.1210/jcem.80.8.7629238>)
- Rohr CO, Parra RG, Yankilevich P & Perez-Castro C 2013 INSECT: IN-Silico SEarch for Co-occurring Transcription factors. *Bioinformatics* **29** 2852–2858. (<https://doi.org/10.1093/bioinformatics/btt506>)
- Rosenfeld MG, Lunyak VV & Glass CK 2006 Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. *Genes and Development* **20** 1405–1428. (<https://doi.org/10.1101/gad.1424806>)
- Schuh TJ & Kimelman D 1995 COUP-TFI is a potential regulator of retinoic acid-modulated development in *Xenopus* embryos. *Mechanisms of Development* **51** 39–49. ([https://doi.org/10.1016/0925-4773\(94\)00346-0](https://doi.org/10.1016/0925-4773(94)00346-0))
- Scully KM & Rosenfeld MG 2002 Pituitary development: regulatory codes in mammalian organogenesis. *Science* **295** 2231–2235. (<https://doi.org/10.1126/science.1062736>)
- Segal E & Widom J 2009 From DNA sequence to transcriptional behaviour: a quantitative approach. *Nature Reviews: Genetics* **10** 443–456. (<https://doi.org/10.1038/nrg2591>)
- Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA & Westphal H 1997 Multistep control of pituitary organogenesis. *Science* **278** 1809–1812. (<https://doi.org/10.1126/science.278.5344.1809>)
- Shi Y & Massague J 2003 Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* **113** 685–700. ([https://doi.org/10.1016/s0092-8674\(03\)00432-x](https://doi.org/10.1016/s0092-8674(03)00432-x))
- Suh H, Gage PJ, Drouin J & Camper SA 2002 Pitx2 is required at multiple stages of pituitary organogenesis: pituitary primordium formation and cell specification. *Development* **129** 329–337.
- Therrien M & Drouin J 1991 Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. *Molecular and Cellular Biology* **11** 3492–3503. (<https://doi.org/10.1128/mcb.11.7.3492>)
- Tsukamoto N, Otsuka F, Miyoshi T, Yamanaka R, Inagaki K, Yamashita M, Otani H, Takeda M, Suzuki J, Ogura T, *et al.* 2010 Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs. *Endocrinology* **151** 1129–1141. (<https://doi.org/10.1210/en.2009-1102>)
- Vilar L, Albuquerque JL, Lyra R, Trovão Diniz E, Rangel Filho F, Gadelha P, Thé AC, Ibiapina GR, Gomes BS, Santos V, *et al.* 2016 The role of isotretinoin therapy for Cushing's disease: results of a prospective study. *International Journal of Endocrinology* **2016** 8173182. (<https://doi.org/10.1155/2016/8173182>)
- Yacqub-Usman K, Duong CV, Clayton RN & Farrell WE 2012 Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced re-expression. *Endocrinology* **153** 3603–3612. (<https://doi.org/10.1210/en.2012-1231>)
- Yacqub-Usman K, Duong CV, Clayton RN & Farrell WE 2013 Preincubation of pituitary tumor cells with the epidrugs zebularine and trichostatin A are permissive for retinoic acid-augmented expression of the BMP-4 and D2R genes. *Endocrinology* **154** 1711–1721. (<https://doi.org/10.1210/en.2013-1061>)
- Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, *et al.* 2000 Negative regulation of BMP/Smad signaling by Tob in osteoblasts. *Cell* **103** 1085–1097. ([https://doi.org/10.1016/s0092-8674\(00\)00211-7](https://doi.org/10.1016/s0092-8674(00)00211-7))
- Yu Z & Xing Y 2006 All-trans retinoic acid inhibited chondrogenesis of mouse embryonic palate mesenchymal cells by down-regulation of TGF-beta/Smad signaling. *Biochemical and Biophysical Research Communications* **340** 929–934. (<https://doi.org/10.1016/j.bbrc.2005.12.100>)

Received in final form 1 August 2019

Accepted 6 August 2019

Accepted Preprint published online 6 August 2019